Bibw2992

A specification of mAb used in this study is shown in Table 1. The ErbB-targeting drugs canertinib, BIBW2992, and BMS-599626, the KIT kinase blockers nilotinib, midostaurin (PKC412) and dasatinib, and the insulin-like growth factor-1 receptor (IGF-1-R) blocker OSI-906, were from Chemietek (Indianapolis, IN). The irreversible ErbB inhibitor pelitinib and the CD33-targeting antibody-conjugate gemtuzumab ozogamicin (mylotarg) were kindly provided by Wyeth (Cambridge, MA). Recombinant human (rh) stem cell factor (SCF) was purchased from Peprotech (Rocky Hill, NJ), rh erythropoietin (EPO) and rh transforming growth factor-β1 (TGF-β1) from R&D Systems (Minneapolis, MN), and rh Heregulin-α (EGF-domain) from Sigma-Aldrich (St. Louis, MO). Dulbecco's modified eagle medium (DMEM) and fetal calf serum (FCS) were from Gibco Life Technologies (Gaithersburg, MD).

LBH589, erlotinib, BIBW2992, WZ4002, BEZ235, and AZD6244 were purchased from Chemie Tek (Indianapolis, IN). PD173074, LY364947, salinomycin, and IWP2 were purchased from Sigma-Aldrich (St. Louis, MO). CNTO328 was provided by Centocor, Inc. (Horsham, PA). CL-387,785 was purchased from AXXORA (San Diego, CA). Stock solutions of these reagents in 100% DMSO were diluted directly into the media to indicated concentrations. Human TGF-β1 was purchased from R&D Systems (Minneapolis, MN).